NASDAQ · Biotechnology

NGNE (NGNE) Stock

$32.90 +0.03% NASDAQ: NGNE Healthcare

Valuation

MetricValue
Price$32.90
Market Cap$519.90M
P/E Ratio-5.25
P/B Ratio1.93
P/S Ratio0.00
EPS (TTM)$-4.24
52-Week High$42.84
52-Week Low$14.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-37.25%
ROA-23.91%
ROCE-38.87%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio17.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$1.0M$0
Operating Profit$-51.0M$-57.0M$-56.0M$-83.0M$-103.0M
Net Profit$-51.0M$-55.0M$-36.0M$-75.0M$-90.0M
EPS$-0.92$-4.30$-2.83$-4.28$-4.24
Op Margin———-8930.3%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$101.0M$109.0M$223.0M$336.0M$289.0M
Total Liabilities$193.0M$11.0M$37.0M$25.0M$24.0M
Cash$71.0M$82.0M$148.0M$137.0M$104.0M
Borrowings$6.0M$5.0M$16.0M$12.0M$10.0M

Latest News

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 6, 2026 Neurogene Prices $125 Million Public Offering MT Newswires · Jul 1, 2026 Neurogene Inc. Announces Pricing of $125 Million Public Offering Business Wire · Jul 1, 2026 Neurogene Launches Public Offering MT Newswires · Jun 30, 2026 Neurogene Inc. Announces Proposed Public Offering Business Wire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-46.0M$-53.0M$-51.0M$-71.0M$-77.0M
Investing Cash Flow$-37.0M$-4.0M$25.0M$-126.0M$13.0M
Financing Cash Flow$0$0$0$-5.0M$0
Net Cash Flow$-14.0M$11.0M$67.0M$-12.0M$-33.0M
Free Cash Flow$-65.0M$-55.0M$-52.0M$-71.0M$-78.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-2.10
FCF Yield-17.81%
Quick Ratio13.08
Interest Coverage—
Return 1Y54.05%
Return 3Y158.13%
Return 5Y-76.63%

Ownership

Insiders Held7.07%
Institutions Held88.49%
Institutions Float Held95.23%
Institutional HolderSharesReport Date
Samsara BioCapital, LLC1,717,1272026-03-31
Redmile Group, LLC1,459,5992026-03-31
Casdin Capital, LLC1,420,3612026-03-31
RTW Investments LP1,362,4562026-03-31
EcoR1 Capital, LLC1,271,3422026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADCTADC Therapeutics S.A. $1.19 +3.48% -1.09 $151.36M 0.00%
ALMS $26.38 -2.40% -7.40 $3.26B 0.00%
AUTLAutolus Therapeutics plc $1.46 -13.61% -1.35 — 0.00%
BNTC $13.07 -0.46% -11.78 $449.01M 0.00%
FULC $3.73 +0.13% -5.17 $201.56M 0.00%

About NGNE

NGNE is led by CEO Rachel L. McMinn, employs 107 people, headquartered in US, publicly traded since 2014.

NGNE stock trades at $32.90 with a market capitalization of $519.90M. The stock is valued at a price-to-earnings (P/E) ratio of -5.25, price-to-book of 1.93, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $14.65 and $42.84, and currently trades 23.2% below its 52-week high.

On profitability, NGNE generates a return on equity (ROE) of -37.25%, return on capital employed of -38.87%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides